Precision’s technology will provide the next-generation vaccines for emerging infectious diseases. PV-ZIKV, our vaccine candidate for Zika, has significant advantages over competitors, including the lack of cross-reactivity among flaviviruses and increased potency

The ability to accomplish precise re-targeting of adenoviral vectors has been a holy grail of the gene therapy and vaccine fields. Precision’s unique technology to accomplish this goal now makes possible vaccine agents which are targeted to the key biologic axes relevant to orchestrating effective immune responses